Identification of putative noncanonical driver mutations in patients with essential thrombocythemia
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13945 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Akihiko Arai und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Hauptthemen laut MEDLINE: Thrombocythemia, Essential, Thrombocytosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Essential thrombocythemia (ET) cases without canonical JAK2 , CALR , or MPL mutations, that is, triple‐negative (TN) ET, have been found in 10%–20% of ET cases. Owing to the limited number of TN ET cases, its clinical significance remains unclear. This study evaluated TN ET's clinical characteristics and identified novel driver mutations. Among 119 patients with ET, 20 (16.8%) had no canonical JAK2/CALR/MPL mutations. Patients with TN ET tended to be younger and had lower white blood cell counts and lactate dehydrogenase values. We identified putative driver mutations in 7 (35%): MPL S204P, MPL L265F, JAK2 R683G, and JAK2 T875N were previously reported as candidate driver mutations in ET. Moreover, we identified a THPO splicing site mutation, MPL *636Wext*12, and MPL E237K. Four of the seven identified driver mutations were germline. Functional studies on MPL *636Wext*12 and MPL E237K revealed that they are gain‐of‐function mutants that increase MPL signaling and confer thrombopoietin hypersensitivity with very low efficiency. Patients with TN ET tended to be younger, although this was thought to be due to the inclusion of germline mutations, hereditary thrombocytosis. Accumulating the genetic and clinical characteristics of noncanonical mutations may help future clinical interventions in TN ET and hereditary thrombocytosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
- Department of Hematology and Rheumatology, Kagoshima City Hospital, Kagoshima, Japan.
- Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
- Department of Hematology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.
- Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
- Department of Hematology, Imakiire General Hospital, Kagoshima, Japan.
ORCID-Profile: Makoto Yoshimitsu, Nobuaki Nakano, Kosuke Obama, Daisuke Nakamura, Masahito Tokunaga, Atae Utsunomiya, Kenji Ishitsuka
Zitieren
APA
Arai, A., Yoshimitsu, M., Otsuka, M., Ito, Y., Miyazono, T., Nakano, N., Obama, K., Nakashima, H., Hanada, S., Owatari, S., Nakamura, D., Tokunaga, M., Kamada, Y., Utsunomiya, A., Haraguchi, K., Hayashida, M., Fujino, S., Odawara, J., Tabuchi, T., …, & Ishitsuka, K. (2023). Identification of putative noncanonical driver mutations in patients with essential thrombocythemia. European Journal of Haematology. https://doi.org/10.1111/ejh.13945
Vancouver
Arai A, Yoshimitsu M, Otsuka M, Ito Y, Miyazono T, Nakano N, et al. Identification of putative noncanonical driver mutations in patients with essential thrombocythemia. European Journal of Haematology. 2023. doi:10.1111/ejh.13945
BibTeX
@article{Arai2023,
author = {Arai, Akihiko and Yoshimitsu, Makoto and Otsuka, Maki and Ito, Yoshikiyo and Miyazono, Takayoshi and Nakano, Nobuaki and Obama, Kosuke and Nakashima, Hidetoshi and Hanada, Shuichi and Owatari, Satsuki and Nakamura, Daisuke and Tokunaga, Masahito and Kamada, Yuhei and Utsunomiya, Atae and Haraguchi, Koichi and Hayashida, Maiko and Fujino, Satoshi and Odawara, Jun and Tabuchi, Tomohisa and Suzuki, Shinsuke and Hamada, Heiichiro and Kawamoto, Yoshiko and Uchida, Yuichiro and Hachiman, Miho and Ishitsuka, Kenji},
title = {Identification of putative noncanonical driver mutations in patients with essential thrombocythemia},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13945}
}
EUVIMED